A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas

Background. Belinostat is a novel histone deacetylase inhibitor. Primary Objectives. Maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of belinostat (Bel) in combination with doxorubicin (Dox) in solid tumours (phase I) and response rate (RR) in soft tissue sarcomas (phase II). Method...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitfell-Rasmussen, Joanna, Judson, Ian, Safwat, Akmal, Jones, Robin L., Rossen, Philip Blach, Lind-Hansen, Maja, Knoblauch, Poul, Krarup-Hansen, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923583/
https://www.ncbi.nlm.nih.gov/pubmed/27403082
http://dx.doi.org/10.1155/2016/2090271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923583/
https://www.ncbi.nlm.nih.gov/pubmed/27403082
http://dx.doi.org/10.1155/2016/2090271

Ejemplares similares